Cooperative effects of soy isoflavones and carotenoids on osteoclast formation

Journal of Clinical Biochemistry and Nutrition

Volumn 54, Issue 2, 2014, Pages 109-115

  Tadaishi, Miki ^a   Nishide, Yoriko ^a   Tousen, Yuko ^a   Kruge, Marlena C ^b   Ishimi, Yoshiko ^a  

^a NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

^b MASSEY UNIVERSITY   (New Zealand)

Author keywords

Bone; Carotenoids; Osteoclast formation; Soy isoflavones

Indexed keywords

CAROTENOID; DAIDZEIN; EQUOL; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOFLAVONE DERIVATIVE; LACTATE DEHYDROGENASE; OSTEOCLAST DIFFERENTIATION FACTOR; XANTHOPHYLL; ZEAXANTHIN;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL COUNT; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; SOYBEAN;

EID: 84897551077     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.13-94     Document Type: Article

References (25)

1. Udagawa N, Takahashi N, Akatsu T, et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 1990; 87: 7260-7264.
2. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319. (Pubitemid 27199902)
3. Kostelac D, Rechkemmer G, Briviba K. Phytoestrogens modulate binding response of estrogen receptors alpha and beta to the estrogen response element. J Ag ric Food Chem 2003; 51: 7632-7635.
4. Taku K, Melby MK, Nishi N, Omori T, Kurzer MS. Soy isoflavones for osteoporosis: an evidence-based approach. Maturitas 2011; 70: 333-338.
5. Karieb S, Fox SW. Phytoestrogens directly inhibit TNF-a-induced bone resorption in RAW264.7 cells by suppressing c-fos-induced NFATcl expression. J Cell Biochem 2011; 112: 476-487.
6. Ohtomo T, Uehara M, Peñalvo JL, et al. Comparative activities of daidzein metabolites, equol and O-desmethylangolensin, on bone mineral density and lipid metabolism in ovariectomized mice and in osteoclast cell cultures. Eur J Nutr 2008; 47: 273-279.
7. Sahni S, Hannan MT, Blumberg J, Cupples LA, Kiel DP, Tucker KL. Protective effect of total carotenoid and lycopene intake on the risk of hip fracture: a 17-year follow-up from the Framingham Osteoporosis Study. J Bone Miner Res 2009; 24: 1086-1094.
8. Sugiura M, Nakamura M, Ogawa K, Ikoma Y, Yano M. High serum carotenoids associated with lower risk for bone loss and osteoporosis in post-menopausal Japanese female subjects: prospective cohort study. PLoS One 2012; 7:e52643.
9. Wattanapenpaiboon N, Lukito W, Wahlqvist ML, Strauss BJ. Dietary carotenoid intake as a predictor of bone mineral density. Asia Pac J Clin Nutr 2003; 12: 467-73. (Pubitemid 38886966)
10. Ishimi Y, Ohmura M, Wang X, Yamaguchi M, Ikegami S. Inhibition by carotenoids and retinoic acid of osteoclast-like cell formation induced by bone-resorbing agents in vitro. J Clin Biochem Nutr 1999; 27: 113-122. (Pubitemid 30471524)
11. Yamaguchi M, Uchiyama S. beta-Cryptoxanthin stimulates bone formation and inhibits bone resorption in tissue culture in vitro. Mol Cell Biochem 2004; 258: 137-144. (Pubitemid 38268208)
12. Das SK, Ren R, Hashimoto T, Kanazawa K. Fucoxanthin induces apoptosis in osteoclast-like cells differentiated from RAW264.7 cells. J Agric Food Chem 2010; 58: 6090-6095.
13. Rao LG, Krishnadev N, Banasikowska K, Rao AV. Lycopene 1 - effect on osteoclasts: lycopene inhibits basal and parathyroid hormone-stimulated osteoclast formation and mineral resorption mediated by reactive oxygen species in rat bone marrow cultures. J Med Food 2003; 6: 69-78. (Pubitemid 37128466)
14. Miller NJ, Sampson J, Candeias LP, Bramley PM, Rice-Evans CA. Antioxidant activities of carotenes and xanthophylls. FEBS Lett 1996; 384: 240-242. (Pubitemid 26125229)
15. Abdel-Aal El-SM, Akhtar H, Zaheer K, Ali R. Dietary sources of lutein and zeaxanthin carotenoids and their role in eye health. Nutrients 2013; 5: 1169-1185.
16. Lin CY, Huang CS, Hu ML. The use of fetal bovine serum as delivery vehicle to improve the uptake and stability of lycopene in cell culture studies. Br J Nutr 2007; 98: 226-232.
17. Nishide Y, Tousen Y, Inada M, Miyaura C, Ishimi Y. Bi-phasic effect of equol on adipocyte differentiation of MC3T3-L1 cells. Biosci Biotechnol Biochem 2013; 77: 201-204.
18. Matsukawa Y, Marui N, Sakai T, et al. Genistein arrests cell cycle progression at G2-M. Cancer Res 1993; 53: 1328-1331. (Pubitemid 23097111)
19. Spinozzi F, Pagliacci MC, Migliorati G, el al. The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leuk Res 1994; 18: 431-439. (Pubitemid 24169825)
20. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3: 889-901. (Pubitemid 35460788)
21. Balkan W, Rodriguez-Gonzalez M, Pang M, Fernandez I, Troen BR. Retinoic acid inhibits NFATc1 expression and osteoclast differentiation. J Bone Miner Metab 2011; 29: 652-661.
22. Moon HJ, Ko WK, Han SW, et al. Antioxidants, like coenzyme Q10, selenite, and curcumin, inhibited osteoclast differentiation by suppressing reactive oxygen species generation. Biochem Biophys Res Commun 2012; 418: 247-253.
23. Lee JH, Kim HN, Yang D, el al. Trolox prevents osteoclastogenesis by suppressing RANKL expression and signaling. J Biol Chem 2009; 284: 13725-13734.
24. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Nall Acad Sci USA 2001; 98: 11581-11586. (Pubitemid 32928771)
25. Roux S, Meignin V, Quillard J, el al. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol 2002; 117: 86-92. (Pubitemid 34304425)